The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Histogenics said it raised another $49 million for its regenerative cartilage treatments, as it proceeds with a clinical trial for its NeoCart treatment and pursues CE Mark approval for its VeriCart system.
The round was led by Sofinnova Ventures and including backing from new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund. Prior backers ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also kicked in.
Histogenics said it raised another $49 million for its regenerative cartilage treatments, as it proceeds with a clinical trial for its NeoCart treatment and pursues CE Mark approval for its VeriCart system.
The round was led by Sofinnova Ventures and including backing from new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund. Prior backers ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also kicked in.
WALTHAM, Mass.–(BUSINESS WIRE)–Regenerative medicine company Histogenics Corporation appoints Michael Lewis, M.D. to CMO and Peter Hamilton to VP of Manufacturing & Production to support Phase 3 development of NeoCart.
Histogenics Corp., fresh from a merger with fellow Bay State firm Prochon Biotech, has no plans for layoffs, contrary to a report in an Israeli journal.
The Globes new outlet, a business daily based in Rishon Le-Zion, Israel, reported yesterday that Histogenics "will make substantial cuts" to its R&D unit in Ness Ziona.
Histogenics Corp. brought in more than $34 million in equity and debt financing after its acquisition of fellow Bay State firm ProChon Biotech Ltd.
The two companies merged in an all-stock deal that brings ProChon CEO Patrick O’Donnell into the Histogenics corner office.
O’Donnell told MassDevice.com last week that a deal has been in the works since the early part of 2011.
A pair of Bay State regenerative medicine firms, Histogenics Corp. and ProChon Biotech Ltd., merged in an all-stock deal that brings ProChon CEO Patrick O’Donnell into the Histogenics corner office.
O’Donnell told MassDevice.com that a deal has been in the works since the early part of 2011.
ProChon Biotech Ltd. touted the results of a study on knee cartilage defect patients treated with its BioCart system.
Thirty-one Israeli patients received the arthroscopically administered treatment to correct a single full-thickness cartilage defect in the femoral condyle, according to the company. The BioCart autologous cartilage system uses proprietary fibroblast growth factor technology to help regenerate damaged cartilage.
ProChon Biotech Ltd. entered into a contract manufacturing agreement with Mississauga, Ontario-based therapeutic protein developer Therapure Biopharma.
The deal is the latest in the Woburn, Mass.-based company’s build-out for its manufacturing infrastructure. ProChon is developing tissue regeneration technology for articular cartilage injuries of the knee and, eventually, other joints.
ProChon Biotech Ltd. hired of Brian Callahan for the role of executive vice president, regulatory and quality affairs.
Callahan’s last job was with EEC & Associates, a global compliance consulting firm for the medical device and pharmaceutical industries. At Prochon he’ll be the company’s liaison to regulatory agencies, including the Food & Drug Administration, European Medical Authorities and Israeli Ministry of Health, in addition to overseeing regulatory strategy, implementation and compliance.
ProChon Biotech Ltd. says it will likely release the results from expanded clinical trials of its BioCart knee cartilage repair treatment by June.
The Woburn, Mass.-based company, which recently raised about $4 million in a convertible bridge loan to finance the trials, said it’s about halfway through the patient enrollment process in the Phase II study and expects results to be released in three months.
ProChon is developing a system to repair damaged cartilage called the BioCart system, which uses proprietary fibroblast growth factor technology to help regenerate damaged cartilage in the knee.
ProChon Biotech Ltd. closed a $3.95 million convertible bridge loan it plans to use to fund ongoing clinical trials and the manufacture of a key element of its BioCart knee repair system.
The Woburn, Mass.-based company, which is developing a system to repair damaged cartilage, said the loan came from prior backers ProChon Holdings B.V. and the Musculoskeletal Transplant Foundation. ProChon’s BioCart system uses a proprietary fibroblast growth factor technology to help regenerate damaged cartilage in the knee.
